SHL Telemedicine (NASDAQ:SHLT) is a global provider of telehealth and remote patient monitoring solutions designed to support chronic disease management and preventive care. The company’s core offering combines proprietary software platforms with connected medical devices to collect and analyze vital signs, enabling healthcare providers, payers and pharmaceutical companies to monitor patients outside of traditional clinical settings. By integrating data from blood pressure monitors, pulse oximeters, glucometers and other IoT-enabled devices, SHL Telemedicine delivers real-time insights that help identify health risks early and support timely interventions.
At the heart of SHL’s product portfolio is CareSignals®, a cloud-based telehealth platform that aggregates patient data, applies analytics and facilitates secure communication among stakeholders. The platform is complemented by a range of home-based medical devices manufactured to ISO standards, enabling remote monitoring of parameters such as blood pressure, ECG, blood glucose and oxygen saturation. SHL also offers chronic care management programs and digital coaching services, pairing its technological infrastructure with clinical oversight and patient education to improve adherence and outcomes.
Founded in 1980 and headquartered in Petah Tikva, Israel, SHL Telemedicine has expanded its footprint to serve markets across North America, Europe, Asia-Pacific and Latin America. Over the decades, the company has entered strategic partnerships with health plans, healthcare systems and pharmaceutical firms to deploy large-scale remote monitoring initiatives. SHL went public on the Nasdaq in 2023, marking a milestone in its growth trajectory and reflecting increased global demand for telehealth solutions spurred by digital transformation trends and the COVID-19 pandemic.
SHL Telemedicine’s leadership team is led by Chairman and CEO Danny Shapira, whose background spans over two decades in medical device innovation and healthcare IT. The executive team includes seasoned professionals in clinical operations, regulatory affairs and global business development. Together, they focus on expanding SHL’s technological capabilities, forging collaborations that drive scale and advancing regulatory approvals in key international markets.
AI Generated. May Contain Errors.
